Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2007; 13(7): 1103-1107
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1103
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1103
Figure 1 A: Section of colon in normal control showing normal structure and architecture (immunohistochemistry, 40 x); B: Section of colon in DNCB control showing extensive NFκ-B (brown) expression in tissue (immunohistochemistry, 40 x); C: Section of colon in sulfasalazine treated group showing limited NFκ-B (brown) expression (immunohistochemistry, 40 x); D: Section of colon in NCB-02 treated group showing minimal NFκ-B (brown) expression (immunohistochemistry, 40 x).
Figure 2 A: Section of colon in normal control showing normal structure and architecture (immunohistochemistry, 40 x); B: Section of colon in DNCB control showing extensive iNos (brown) expression in tissue (immunohistochemistry, 40 x), C: Section of colon in sulfasalazine treated group showing limited iNos (brown) expression (immunohistochemistry, 40 x); D: Section of colon in NCB-02 treated group showing minimal iNos (brown) expression (immunohistochemistry, 40 x).
- Citation: Venkataranganna M, Rafiq M, Gopumadhavan S, Peer G, Babu U, Mitra S. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFκ-B and iNOS. World J Gastroenterol 2007; 13(7): 1103-1107
- URL: https://www.wjgnet.com/1007-9327/full/v13/i7/1103.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i7.1103